Large-cap stocks usually command their industries because they have the scale to drive market trends.
The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
Shares of clinical research company IQVIA (NYSE: IQV)
jumped 3% in the afternoon session on continued positive momentum after the company reported better-than-expected second-quarter earnings and received several price target increases from Wall Street analysts.
Clinical research company IQVIA (NYSE: IQV) announced better-than-expected revenue in Q2 CY2025, with sales up 5.3% year on year to $4.02 billion. The company’s full-year revenue guidance of $16.2 billion at the midpoint came in 0.8% above analysts’ estimates. Its non-GAAP profit of $2.81 per share was 1.4% above analysts’ consensus estimates.
Shares of clinical research company IQVIA (NYSE: IQV)
jumped 15.9% in the morning session after the company reported second-quarter financial results that beat Wall Street expectations and raised its full-year profit guidance.
Let's delve into the developments on the US markets in the middle of the day on Tuesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Clinical research company IQVIA (NYSE: IQV) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 5.3% year on year to $4.02 billion. The company’s full-year revenue guidance of $16.2 billion at the midpoint came in 0.8% above analysts’ estimates. Its non-GAAP profit of $2.81 per share was 1.4% above analysts’ consensus estimates.
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 3.5%. This performance was disheartening since the S&P 500 gained 4.5%.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how IQVIA (NYSE:IQV) and the rest of the drug development inputs & services stocks fared in Q1.
